138 related articles for article (PubMed ID: 11851570)
1. Do patents prevent access to drugs for HIV in developing countries?
Selgelid MJ; Schuklenk U
JAMA; 2002 Feb; 287(7):842-3. PubMed ID: 11851570
[No Abstract] [Full Text] [Related]
2. Do patents prevent access to drugs for HIV in developing countries?
Goemaere E; Kaninda AV; Ciaffi L; Mulemba M; t Hoen E; Pécoul B
JAMA; 2002 Feb; 287(7):841-2; author reply 842-3. PubMed ID: 11851569
[No Abstract] [Full Text] [Related]
3. Do patents prevent access to drugs for HIV in developing countries?
Boelaert M; Lynen L; Van Damme W; Colebunders R
JAMA; 2002 Feb; 287(7):840-1; author reply 842-3. PubMed ID: 11851568
[No Abstract] [Full Text] [Related]
4. The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.
Sidibé M
Antivir Ther; 2014; 19 Suppl 3():3-4. PubMed ID: 25310132
[No Abstract] [Full Text] [Related]
5. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
6. Affordable drug access for developing countries.
Highleyman L
BETA; 2001; 14(2):12-25. PubMed ID: 11785481
[No Abstract] [Full Text] [Related]
7. Trade systems in less-developed countries.
Kamal Smith M; 't Hoen E
Lancet; 2001 May; 357(9268):1624. PubMed ID: 11386324
[No Abstract] [Full Text] [Related]
8. India: New patent law may restrict access to HIV/AIDS treatments.
Cruess G
HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
[TBL] [Abstract][Full Text] [Related]
9. Global patent police block cost-reduction efforts.
Kasper T
GMHC Treat Issues; 1999 Mar; 13(3):1-2. PubMed ID: 11366201
[TBL] [Abstract][Full Text] [Related]
10. Production of antiretroviral drugs in middle- and low-income countries.
Pinheiro Edos S; Brüning K; Macedo MF; Siani AC
Antivir Ther; 2014; 19 Suppl 3():49-55. PubMed ID: 25310755
[TBL] [Abstract][Full Text] [Related]
11. Health, trade, and industry officials set to debate access to essential drugs.
Kapp C
Lancet; 2001 Apr; 357(9262):1105. PubMed ID: 11297977
[No Abstract] [Full Text] [Related]
12. Access to treatment for HIV/AIDS: a human rights issue in the developing world.
Joni J
Conn J Int Law; 2002; 17(2):273-80. PubMed ID: 12688296
[No Abstract] [Full Text] [Related]
13. Access to HIV drugs: are we changing the two world paradigm?
Lazzarini Z
Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
[No Abstract] [Full Text] [Related]
14. New 20 year patents threaten to end AIDS drugs for developing countries.
Dyer O
BMJ; 2004 Dec; 329(7478):1308. PubMed ID: 15576738
[No Abstract] [Full Text] [Related]
15. Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?
Attaran A; Gillespie-White L
JAMA; 2001 Oct; 286(15):1886-92. PubMed ID: 11597292
[TBL] [Abstract][Full Text] [Related]
16. Canada's plan to sell generic drugs to developing countries is threatened.
Spurgeon D
BMJ; 2004 Mar; 328(7442):728. PubMed ID: 15044278
[No Abstract] [Full Text] [Related]
17. The discovery and development of antiretroviral agents.
Lange JM; Ananworanich J
Antivir Ther; 2014; 19 Suppl 3():5-14. PubMed ID: 25310317
[TBL] [Abstract][Full Text] [Related]
18. Africa access news.
James JS
AIDS Treat News; 2001 Oct; (372):7-8. PubMed ID: 11702415
[No Abstract] [Full Text] [Related]
19. Access to essential drugs, human rights and global justice.
Shalev C
Monash Bioeth Rev; 2004 Jan; 23(1):S56-74. PubMed ID: 15835024
[No Abstract] [Full Text] [Related]
20. Public health. HIV/AIDS treatment for millions.
Binswanger HP
Science; 2001 Apr; 292(5515):221-3. PubMed ID: 11305311
[No Abstract] [Full Text] [Related]
[Next] [New Search]
